Solid Lipid Nanoparticles (SLNPs): Advanced Potential Carriers for Targeting Antipsychotic Medications in the Treatment of Psychotic Disorders.

Abstract

Solid Lipid Nanoparticles (SLNPs) are emerging as advanced nanocarriers that combine the advantages of conventional drug delivery systems with enhanced stability, Bioavailability (BA), and targeted delivery capabilities. These features make them highly promising for therapeutic applications for the treatment of psychotic conditions. This study explores the potential of SLNPs as cutting- edge carriers for antipsychotic drug targeting, emphasising their role in overcoming challenges associated with conventional therapies. A review was conducted using multiple electronic databases, including PubMed, Scopus, official websites, Google Scholar, Google Patent, and ResearchGate. Original research and review articles published between August 31, 2009, and August 31, 2024, were analyzed. From an initial pool of over 100 publications, 60 studies, and an additional 30 relevant articles were selected for review. These results highlight the versatility of SLNPs in addressing therapeutic challenges, particularly in neurological applications like antipsychotic drug targeting. SLNPs represent a cutting-edge advancement in nanotechnology, offering a transformative approach for antipsychotic drug targeting. To enhance drug bioavailability, enable controlled release, and improve blood-brain barrier penetration, SLNPs address critical limitations of conventional therapies. This review underscores the potential of SLNPs as an innovative solution in neuropharmacology, paving the way for future research and clinical applications.